BiondVax is a publicly traded biopharmaceutical company developing a Universal Flu Vaccine, providing multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic.
With 6 completed clinical trials, BiondVax is preparing for its first pivotal clinical efficacy Phase 3 trial.
In the News
“Is this the end of flu? Israel’s BiondVax develops universal flu vaccine” [18 Feb. 2016]